How do the dermatologist perceive the efficacy data of new approvals in atopic dermatitis?
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
© 2024 MMIT